Boulder Hill Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Boulder Hill Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-44,450	Closed	-$6.1M	–	48
2024 Q1	$6.1M	Buy	44,450 +30,200	+212%	+$4.12M	2.51%	2
2023 Q4	$1.94M	Sell	14,250 -43,000	-75%	-$5.25M	1.04%	60
2023 Q3	$7M	Buy	57,250 +1,500	+3%	+$191K	4.35%	6
2023 Q2	$7.08M	Buy	55,750 +29,200	+110%	+$3.79M	13.63%	2
2023 Q1	$3.43M	Sell	26,550 -36,600	-58%	-$4.79M	2.76%	5
2022 Q4	$8.29M	Buy	+63,150	New	+$8.16M	6.89%	3
2022 Q3	–	Sell	-67,885	Closed	-$7.99M	–	162
2022 Q2	$7.99M	Buy	67,885 +485	+0.7%	+$57.6K	9.12%	1
2022 Q1	$8.78M	Buy	67,400 +15,300	+29%	+$1.99M	4.72%	4
2021 Q4	$7.95M	Buy	+52,100	New	+$8.07M	7.7%	1

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Boulder Hill Capital Management's IBB Position: Q2 2024 in Review

Boulder Hill Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 44,450 shares — an estimated $6.1M sold.

Boulder Hill Capital Management first reported a position in IBB in Q4 2021 and held it in 9 quarters. The position peaked at $8.78M in Q1 2022. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

Boulder Hill Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
Boulder Hill Capital Management sold 44,450 iShares Biotechnology ETF shares in Q2 2024, an estimated $6.1M.
Boulder Hill Capital Management first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 9 quarters.
Boulder Hill Capital Management's iShares Biotechnology ETF position peaked at $8.78M in Q1 2022.
894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Boulder Hill Capital Management's 13F filing for Q2 2024.